然而,近年来,有一批HER2表达水平低(HER2-low)的乳腺癌患者引起了研究者的关注。这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 ...
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
Cardiac adverse events such as decreased ejection fraction and heart failure have been of particular concern in patients with HER2+breast cancer. Anti-HER2 agents and chemotherapies (specifically anthracyclines, which are frequently used to treat HER2+disease) have been associated with cardiotoxicity. ...
目前,HER2 低表 达乳腺癌的生物学特征尚不十分明确,HER2 低表达与 HER2 零表达患者预后以及传统治疗 反应差异亦不明确。该研究旨在明确 HER2 低表达与 HER2 零表达早期乳腺癌(eBC)患者 新辅助化疗(NAC)后的化疗敏感性和长期预后。 研...
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2+ breast cancer.
The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed. This is a modal window. The Playback API request failed for an unknown reason Error Code: VIDEO_CLOUD_ERR_UNKNOWN ...
Herceptin is approved for the treatment of adults with early-stage breast cancer that isHumanEpidermal growth factorReceptor2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the ...
In recent years, the treatment of HER2-positive breast cancer has attracted much attention, the anti-HER2-targeted drugs can significantly improve the therapeutic effect of HER2-positive breast cancer patients. In this paper, the research progress in targeted therapy for HER2-positive breast cancer ...
TRUQAP® (capivasertib) is a prescription medication in combination with fulvestrant that is targeted for patients with HR+/HER2- breast cancer with one or more PIK3CA/AKT1/PTEN alteration.
Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer ...